Streetbeat News

Revenues

MIRM

Analyst ratings for Mirum Pharmaceuticals (NASDAQ:MIRM) show a mix of bullish and somewhat bullish opinions, with recent actions including ratings adjustments and price target changes. The average 12-month price target is $52.00, with a recent decrease of 2.42%. Mirum Pharmaceuticals, a biopharmaceutical company, has shown significant revenue growth and strong financial performance despite a high debt-to-equity ratio. Analysts' actions reflect market conditions and company performance, with recent updates indicating a positive but cautious outlook.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 1:00 pm

MCHI

Chinese exporters at the Canton Fair are facing challenges despite China's 5.3% economic growth in Q1, including a decline in exports and producer prices. Increased economic and political tensions with the U.S., global trade slowdowns, and manufacturing overcapacity are key issues. Some sectors, like high-tech, remain optimistic due to government support. Trade tensions could worsen with potential U.S. tariffs and blacklisting of Chinese companies. The iShares MSCI China ETF (MCHI) saw a 1.02% dip.

Portfolio Pulse from Benzinga Neuro

April 17, 2024 | 12:58 pm

SRM

SRM Entertainment, Inc. (NASDAQ:SRM) announced receiving an order for over 36,000 Misting Fans, valued at approximately $900,000, from a longstanding Orlando theme park customer. These custom-designed fans, popular among theme park visitors for staying cool, are set to be delivered in time for the summer season.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:43 pm

MAMO

Massimo Group reported a full year 2023 revenue of $115 million.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:39 pm

XPER

Xperi Inc. has issued a letter to its stockholders, urging them to vote for its five director nominees at the upcoming Annual Meeting on May 24, 2024. The letter highlights Xperi's transformation from a semiconductor IP licensing company to a consumer entertainment technology company, focusing on connected TV advertising, streaming television, and in-vehicle infotainment. Xperi's board and management have driven this change, notably through acquisitions like DTS and the merger with TiVo. The company has seen five consecutive quarters of year-over-year revenue growth and expects continued growth and margin expansion. Xperi is contesting Rubric Capital's campaign to replace two directors, arguing that Rubric's nominees lack relevant experience and could hinder the company's progress.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:35 pm

CXAI

INVO

VNDA

Vanda Pharmaceuticals (VNDA) shares surged 50% after announcing proposals to acquire Vanda Pharmaceuticals, with the latest offer still under consideration. INVO BioScience (INVO) shares jumped 127% following a report of increased Q4 revenue and a projection to reach break-even or profitability by 2024. CXApp (CXAI) shares rose 35% after reporting a 24% growth in Annual Recurring Revenue (ARR) for 2023.

Portfolio Pulse from ryanfaloona@benzinga.com

April 17, 2024 | 12:33 pm

JNVR

Janover, a platform connecting commercial real estate professionals with lenders, reported a 445% increase in sign-ups from 'other' categories, including debt funds, private groups, life insurance companies, family offices, and REITs.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:30 pm

JNVR

Janover Inc. has reported a significant 647% increase in credit union originator sign-ups in 2023, indicating a substantial growth in its business operations and potential expansion in its market reach.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:30 pm

JNVR

Janover Inc. reported a significant 766% increase in banking originator sign-ups on its fintech platform in 2023, indicating strong growth and adoption of its services.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:30 pm

PLD

Prologis (NYSE:PLD) reported its Q1 2024 Core FFO at $1.28 per share, meeting analyst estimates, with a 4.92% increase from the previous year. However, its sales of $1.828 billion fell short of the $1.865 billion estimate, marking a 1.99% miss but an 11.87% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 12:08 pm